MediWound’s first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness ...

A webcast of the presentations will be available on the Investor Relations section of the Vericel Corporation website at: https://investors.vcel.com.

MediWound’s first drug, NexoBrid ®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need ...

MediWound’s first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need ...

Equities researchers at HC Wainwright cut their FY2025 earnings per share (EPS) estimates for Vericel in a report issued on ...

Truist Financial Corp grew its position in shares of Vericel Co. (NASDAQ:VCEL – Free Report) by 1.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 51,827 shares of ...

So as I mentioned, we have two products. The first one on the left is NexoBrid. NexoBrid is a drug for eschar removal for severe burns. In order to remove SCAR in burns, this was horrible image on ...

So as I mentioned, we have two products. The first one on the left is NexoBrid. NexoBrid is a drug for eschar removal for severe burns. In order to remove SCAR in burns, this was horrible image on the ...

Non-GAAP adjusted EBITDA for the quarter ended December 31, 2024 was $29.9 million, or 40% of net revenue, compared to $22.3 million, or 34% of net revenue, for the fourth quarter of 2023. A table ...